Published this week in PLOS Biology, the study by Professor Tony Green and his team at the Cambridge Institute for Medical Research (CIMR) is the first to isolate highly purified single stem cells and study their individual responses to a mutation that can predispose individuals to a human malignancy. This mutation is in a gene called JAK2, which is present in most patients with myeloproliferative neoplasms (MPNs)—a group of bone marrow diseases that are characterized by the over-production of mature blood cells and by an increased risk of developing leukemia.
Using a unique mathematical modeling approach, carried out in collaboration with Professor Ben Simons at the Cavendish Laboratory in Cambridge, in combination with experiments on single mouse stem cells, the researchers identified a distinct cellular mechanism that operates in stem cells but not in their daughter cells.
Read the full story
Image: A small colony of cells derived from a single blood stem cell. Hundreds of such colonies were assessed for their proliferation kinetics and blood cell types produced.
Credit: David Kent, Tony Green Lab
Reproduced courtesy of the University of Cambridge
____________________________________________
Unraveling tumor growth one stem cell at a time
6 June 2013
Researchers at the University of Cambridge have discovered that a single mutation in a leukemia-associated gene reduces the ability of blood stem cells to make more blood stem cells, but leaves their progeny daughter cells unaffected. Their findings have relevance to all cancers that are suspected to have a stem cell origin as they advance our understanding of how single stem cells are subverted to cause tumors.